EJ Topol, GW Falk - The Lancet, 2004 - Elsevier The first agents to block cyclo-oxygenase 2 (COX2) were commercially introduced
5 years ago as new alternatives to existing non-steroidal anti-inflammatory
drugs (NSAIDs). However, the pivotal trials of the first two COX2 ... Cited by 101 - Related articles - All 2 versions
- ►uchicago.edu [PDF] C Dai, RS Stafford, GC Alexander - Archives of Internal Medicine, 2005 - archinte.highwire.org Background The withdrawal of rofecoxib has highlighted concerns regarding the
safety of cyclooxygenase-2 (COX-2) inhibitors. In some patients COX-2 inhibitors
may be safer than nonselective nonsteroidal anti-inflammatory drugs ... Cited by 81 - Related articles - All 11 versions
- ►annals.org [PDF] F Kanwal, IM Gralnek, P Martin, GS Dulai, M … - Annals of internal medicine, 2005 - Am Coll Physicians Background: Treatment options for chronic hepatitis B virus (HBV) infection have
disparate risks and benefits. Interferon has clinically significant side
effects, and lamivudine is associated with viral resistance. In contrast, ... Cited by 65 - Related articles - All 9 versions
BMR Spiegel, CF Chiou, JJ Ofman - Arthritis and Rheumatism-Arthritis Care and Research, 2005 - researchcore.org Objective. To appraise the cost-effectiveness of competing therapeutic
strategies in patient cohorts eligible for aspirin prophylaxis with varying
degrees of gastrointestinal (GI) and cardiovascular risk. Methods. Cost- ... Cited by 53 - Related articles - View as HTML - All 8 versions
SG Leveille - Current opinion in rheumatology, 2004 - journals.lww.com Purpose of review Chronic conditions associated with musculoskeletal aging
contribute to a heavy functional and economic burden for our rapidly aging
population. The purpose of this article is to review recent investigations ... Cited by 46 - Related articles - BL Direct - All 6 versions
JL Goldstein, B Huang, F Amer, NG … - Clinical therapeutics, 2004 - Elsevier This post hoc subanalysis was based on a previous multicenter, prospective,
randomized, double-blind, placebo-controlled, 12-week study in patients who had
a history of gastric ulcer, were Helicobacter pylori negative, required ... Cited by 32 - Related articles - All 3 versions
- ►researchcore.org [PDF] BMR Spiegel, M Farid, GS Dulai, IM Gralnek, … - The American Journal of Medicine, 2006 - Elsevier Because dyspeptic symptoms are far more prevalent than ulcer complications in
users of nonsteroidal anti-inflammatory drugs (NSAIDs), economic models indicate
that dyspepsia rates (not ulcer complications) are the major determinant of ... Cited by 31 - Related articles - All 15 versions
F Kanwal, M Farid, P Martin, G Chen, IM … - American Journal of Gastroenterology, 2006 - sovegastro.com Fasiha Kanwal, MD, MSHS,1–4 Mary Farid, DO,1,3 Paul Martin, MD,6 Gary Chen,
MD,6 Ian M. Gralnek, MD, MSHS,2,3 Gareth S. Dulai, MD, MSHS,2,3 and Brennan MR
Spiegel, MD, MSHS1–4 1Division of Gastroenterology, VA Greater Los ... Cited by 28 - Related articles - View as HTML - BL Direct - All 9 versions
US Akarca - Current pharmaceutical design, 2005 - ingentaconnect.com Abstract: Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most
commonly prescribed group of drugs. Patients receiving NSAIDs often experience
abdominal discomfort, and some of them develop serious gastrointestinal ... Cited by 27 - Related articles - All 5 versions
S Schneeweiss, RJ Glynn, J Avorn, DH … - Journal of clinical epidemiology, 2005 - Elsevier A cohort of 37,957 Medicare beneficiaries who were enrolled in the
Pharmaceutical Assistance Contract for the Elderly in Pennsylvania was
identified. All patients had started using nonselective nonsteroidal anti- ... Cited by 26 - Related articles - All 12 versions
